Company Overview and News

0
APA backs CKI's $13b gas pipeline takeover

2018-08-12 theage.com.au
The board of Australian gas pipeline giant APA has unanimously backed Hong Kong-based utility firm CKI’s $13 billion takeover.
1038 HGKGF CKISY HGKGY CKISF DUETF DUE

0
APA backs CKI's $13b gas pipeline takeover

2018-08-12 smh.com.au
The board of Australian gas pipeline giant APA has unanimously backed Hong Kong-based utility firm CKI’s $13 billion takeover.
1038 HGKGF CKISY HGKGY CKISF DUETF DUE

0
Victor Li's CKI attempts biggest-ever deal with A$13b APA bid

2018-06-13 malaymail
HONG KONG, June 13 — Hong Kong’s Cheung Kong Infrastructure Holdings Ltd offered A$13 billion (RM39.4 billion) for Australian gas pipelines company APA Group, as new chairman Victor Li starts his tenure attempting the company’s biggest-ever takeover.
1038 HGKGF CKISY HGKGY CKISF DUETF APA DUE

0
Waste Management profit rises in 2017

2018-05-16 nzherald.co.nz
Waste Management, New Zealand's biggest waste collection and recycling company, drove up sales and profit last year as economic growth underpinned volumes of industrial and construction sector waste and it added landfill capacity.
1038 CKISY WM CKISF

1
Decades-long apprenticeship of Li Ka-shing's son is finally over

2018-03-19 thestar.com.my
Whispering in dad's ear: Hong Kong tycoon Li Ka-shing, right, chairman of CK Hutchison Holdings company, chats with his son, co-managing directors Victor Li attend a press conference to announce the company's annual results in Hong Kong, Friday, March 16, 2018. Hong Kong billionaire Li said Friday he is retiring as chairman of his sprawling conglomerate and handing control to his eldest son. - AP
1038 ACDVF CKHUF CKISY CKHUY CKISF DUETF AC DUE

1
Victor Li finally emerges from the shadow of his Superman father Li Ka-shing

2018-03-16 scmp
Victor, a Stanford University-educated engineer, takes over control of CK Hutchison Holdings and CK Asset Holdings after a decades-long apprenticeship under his illustrious father
1038 ACDVF CKHUF CKISY CKHUY CKISF DUETF AC DUE

0
Shares of Li Ka-shing’s Power Assets surge on special dividend and higher profit 

2018-03-16 scmp
The Hong Kong-listed utilities company makes a net profit of HK$8.32 billion for 2017, beating analysts’ estimates
1038 HGKGF CKISY HGKGY CKISF

Related Articles

REPH: Recro Pharma Analysis and Research Report

2018-08-20 - Asif

Overview Recro Pharma is a specialty pharmaceutical company that operates through two business divisions: an Acute Care division and a revenue-generating CDMO division. Each of these divisions are deemed to be reportable segments for financial reporting purposes. The company's Acute Care segment is primarily focused on developing and commercializing innovative products for hospital and related acute care settings. The company's lead product candidate is a proprietary injectable form of meloxicam, a long-acting preferential COX-2 inhibitor. IV meloxicam has successfully completed three Phase III clinical trials for the management of moderate to severe pain, consisting of two pivotal efficacy trials and a large double-blind Phase III safety trial, as well as other safety studies. Overall, the total new drug application, or NDA, program included over 1,400 patients. In late July 2017, the company submitted a NDA to the U.S. Food and Drug Administration, or FDA, for IV meloxicam...

ACHN: Achillion Pharmaceuticals Analysis and Research Report

2018-08-20 - Asif

Overview Achillion Pharmaceuticals is a clinical-stage biopharmaceutical company focused on advancing its oral factor D inhibitors into late-stage development and commercialization. Each of the drug candidates in its oral factor D portfolio was discovered in its laboratories and is wholly owned by it. Achillion Pharmaceuticals is focusing its drug development activities on alternative pathway-mediated, rare diseases where there are no approved therapies or where existing therapies are inadequate for patients. To advance its investigational drugs into phase III and commercialization, the company plan to work closely with key stakeholders including patients, payors, regulators and healthcare professionals. The company's first-generation factor D inhibitor, ACH-4471, has demonstrated preliminary clinical proof-of-concept in patients with C3 glomerulopathy, or C3G, a disease affecting the kidney, and paroxysmal nocturnal hemoglobinuria, or PNH, a blood disorder, and has advanced...

BTE: Baytex Energy Trust Analysis and Research Report

2018-08-20 - Asif

General Baytex Energy Corp. was incorporated on October 22, 2010 pursuant to the provisions of the ABCA. Baytex is the successor to the business of Baytex Energy Trust, which was transitioned to Baytex on December 31, 2010. Inter-Corporate Relationships The following table provides the name, the percentage of voting securities owned by it and the jurisdiction of incorporation, continuance, formation or organization of its material subsidiaries either, direct and indirect, as at the date hereof. ||Percentage of voting securities (directly or indirectly)|Jurisdiction of Incorporation/Formation| | ------------ | ------------: | :------------: | |Baytex Energy Ltd.|100%|Alberta| |Baytex Energy USA, Inc.|100%|Delaware| |Baytex Energy Partnership|100%|Alberta| Organizational Structure The following simplified diagram shows the inter-corporate relationships among it and its material subsidiaries as of the date hereof. <img src="https://www.sec.gov/A...